A Real-world Study to Evaluate the Effectiveness of Deucr... | NCT06701513 | Trialant

A Real-world Study to Evaluate the Effectiveness of Deucr... | NCT06701513 | Trialant

Arms/Interventions Module

Outcomes Module

Primary Outcomes

Measure	Description	Time Frame
Physician's Global Assessment (PGA) 0/1 response		Baseline and at months 4, 12, 18 (optional), and 24
Dermatology Life Quality Index (DLQI) 0/1 response		Baseline and at months 4, 12, 18 (optional), and 24
Time from date of treatment initiation to date of discontinuation		Up to 24 months

Secondary Outcomes

Measure	Description	Time Frame
Change in percentage involved Body Surface Area (BSA) from start of deucravacitinib treatment		Baseline and at months 4, 12, 18 (optional), and 24
Change in patient reported symptom burden as assed by the 100-point Visual Analog Scale (VAS) - Itch		Baseline and months 1, 4, 12, 18 (optional) and 24

Contacts/Locations Module

Central Contacts

Name	Role	Phone	Extension	Email
BMS Clinical Trials Contact Center www.BMSClinicalTrials.com	Contact	855-907-3286		Clinical.Trials@bms.com
First line of the email MUST contain NCT # and Site #.	Contact